» Authors » Anna E Pawlowski

Anna E Pawlowski

Explore the profile of Anna E Pawlowski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 530
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cunningham C, Pawlowski A, Schaidle S
J Pharm Pract . 2024 Sep; :8971900241287614. PMID: 39325975
Angiotensin II (ATII) has been shown in the literature to increase the risk of thrombosis. Little data exists in patients with mechanical circulatory support (MCS) due to exclusion from landmark...
2.
Rivera A, Pierce J, Sinha A, Pawlowski A, Lloyd-Jones D, Lee Y, et al.
PLoS One . 2024 Jun; 19(6):e0305467. PMID: 38875273
Background: Emulation of the "target trial" (TT), a hypothetical pragmatic randomized controlled trial (RCT), using observational data can be used to mitigate issues commonly encountered in comparative effectiveness research (CER)...
3.
Rhodes N, Rohani R, Yarnold P, Pawlowski A, Malczynski M, Qi C, et al.
Antimicrob Agents Chemother . 2022 Dec; 67(1):e0102322. PMID: 36472425
Methicillin-resistant Staphylococcus aureus (MRSA) is an uncommon but serious cause of community-acquired pneumonia (CAP). A lack of validated MRSA CAP risk factors can result in overuse of empirical broad-spectrum antibiotics....
4.
Rohani R, Scheetz M, Donnelly H, Donayre A, Kang M, Diaz E, et al.
J Antimicrob Chemother . 2022 Jul; 77(11):2956-2959. PMID: 35869779
Objectives: Critical illness reduces β-lactam pharmacokinetic/pharmacodynamic (PK/PD) attainment. We sought to quantify PK/PD attainment in patients with hospital-acquired pneumonia. Methods: Meropenem plasma PK data (n = 70 patients) were modelled,...
5.
Sinha A, Rivera A, Chadha S, Prasada S, Pawlowski A, Thorp E, et al.
Front Cardiovasc Med . 2021 Dec; 8:757738. PMID: 34859072
Chronic inflammatory diseases (CIDs) are considered risk enhancing factors for coronary heart disease (CHD). However, sparse data exist regarding relative CHD risks across CIDs. Determine relative differences in CHD risk...
6.
Grant R, Morales-Nebreda L, Markov N, Swaminathan S, Guzman E, Abbott D, et al.
bioRxiv . 2021 May; PMID: 34013276
One Sentence Summary: SARS-CoV-2-infected alveolar macrophages form positive feedback loops with T cells in patients with severe COVID-19.
7.
Grant R, Morales-Nebreda L, Markov N, Swaminathan S, Querrey M, Guzman E, et al.
Nature . 2021 Jan; 590(7847):635-641. PMID: 33429418
Some patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop severe pneumonia and acute respiratory distress syndrome (ARDS). Distinct clinical features in these patients have led to speculation...
8.
Prasada S, Rivera A, Nishtala A, Pawlowski A, Sinha A, Bundy J, et al.
JACC Heart Fail . 2020 Apr; 8(6):489-498. PMID: 32278678
Objectives: The purpose of this study was to compare the risks of incident heart failure (HF) among a variety of chronic inflammatory diseases (CIDs) and to determine whether risks varied...
9.
Feinstein M, Steverson A, Ning H, Pawlowski A, Schneider D, Ahmad F, et al.
J Am Heart Assoc . 2018 Dec; 7(21):e009985. PMID: 30571387
Background HIV is associated with elevated risk of heart failure ( HF ). Despite poor agreement between automated, administrative code-based HF definitions and physician-adjudicated HF , no studies have evaluated...
10.
Sanders J, Steverson A, Pawlowski A, Schneider D, Achenbach C, Lloyd-Jones D, et al.
PLoS One . 2018 Mar; 13(3):e0194754. PMID: 29558525
Background: Human Immunodeficiency Virus-Infected (HIV+) persons have elevated risks for various manifestations of cardiovascular disease (CVD). No studies to our knowledge have compared atrial fibrillation (AF) and atrial flutter (AFL)...